Aaron M Gazendam1, Patricia Schneider2, Andre Spiguel3, Michelle Ghert2. 1. Division of Orthopaedics, Department of Surgery, St. Joseph's Hospital, McMaster University, Hamilton, ON, Canada. aaron.gazendam@gmail.com. 2. Division of Orthopaedics, Department of Surgery, St. Joseph's Hospital, McMaster University, Hamilton, ON, Canada. 3. Department of Orthopaedics and Rehabilitation, University of Florida College of Medicine, Gainesville, FL, USA.
Abstract
INTRODUCTION: Sarcoma patients undergoing surgical resection and endoprosthetic reconstruction often receive neoadjuvant chemotherapy (NACT). The objective of the current study was to determine if the timing of NACT impacts the rates of surgical site infections (SSI) and reoperations. METHODS: This study was a secondary analysis of the recently published Prophylactic Antibiotic Regimens in Tumor Surgery trial. Patients who underwent NACT, tumor resection, and endoprosthetic reconstruction for a bone or soft tissue sarcoma were included. Multivariate Cox proportional hazards regression models were created to evaluate if NACT timing was predictive of SSI or reoperations. RESULTS: Overall, 216 patients from 39 clinical sites were included in the analysis. The most common diagnosis was osteosarcoma (75%), followed by Ewing's sarcoma (16%). The median time from completion of NACT to surgery was 24 days (interquartile range 15-42 days). Eighty-five (39%) patients underwent surgery within 3 weeks of completing NACT, 78 (36%) underwent surgery 3-6 weeks after completing NACT, and 53 (22%) patients underwent surgery > 6 weeks after completion of NACT. The timing of NACT did not impact SSI rates or reoperation rates. Longer operative time was an independent predictor of both SSI [hazard ratio (HR) per hour of 1.21, 95% confidence interval (CI) 1.07-1.40; p = 0.002] and reoperation rates (HR of 1.15 per hour, 95% CI 1.03-1.28; p = 0.014). CONCLUSION: The timing of surgery following NACT varied considerably. Chemotherapy timing did not impact SSI or reoperations in patients undergoing surgical resection and endoprosthetic reconstruction in sarcoma patients.
INTRODUCTION: Sarcoma patients undergoing surgical resection and endoprosthetic reconstruction often receive neoadjuvant chemotherapy (NACT). The objective of the current study was to determine if the timing of NACT impacts the rates of surgical site infections (SSI) and reoperations. METHODS: This study was a secondary analysis of the recently published Prophylactic Antibiotic Regimens in Tumor Surgery trial. Patients who underwent NACT, tumor resection, and endoprosthetic reconstruction for a bone or soft tissue sarcoma were included. Multivariate Cox proportional hazards regression models were created to evaluate if NACT timing was predictive of SSI or reoperations. RESULTS: Overall, 216 patients from 39 clinical sites were included in the analysis. The most common diagnosis was osteosarcoma (75%), followed by Ewing's sarcoma (16%). The median time from completion of NACT to surgery was 24 days (interquartile range 15-42 days). Eighty-five (39%) patients underwent surgery within 3 weeks of completing NACT, 78 (36%) underwent surgery 3-6 weeks after completing NACT, and 53 (22%) patients underwent surgery > 6 weeks after completion of NACT. The timing of NACT did not impact SSI rates or reoperation rates. Longer operative time was an independent predictor of both SSI [hazard ratio (HR) per hour of 1.21, 95% confidence interval (CI) 1.07-1.40; p = 0.002] and reoperation rates (HR of 1.15 per hour, 95% CI 1.03-1.28; p = 0.014). CONCLUSION: The timing of surgery following NACT varied considerably. Chemotherapy timing did not impact SSI or reoperations in patients undergoing surgical resection and endoprosthetic reconstruction in sarcoma patients.
Authors: Alex J Anatone; Nicholas C Danford; Eugene S Jang; Anne Smartt; Matthew Konigsberg; Wakenda K Tyler Journal: J Am Acad Orthop Surg Date: 2020-10-15 Impact factor: 3.020
Authors: Steve R Martinez; Anthony S Robbins; Frederick J Meyers; Richard J Bold; Vijay P Khatri; James E Goodnight Journal: Cancer Date: 2008-03-01 Impact factor: 6.860
Authors: Thomas L Sutton; Nathalie Johnson; Alexander Schlitt; Stuart K Gardiner; Jennifer R Garreau Journal: Am J Surg Date: 2020-03-10 Impact factor: 2.565
Authors: Hamayun Imran; Felicity Enders; Mark Krailo; Franklin Sim; Scott Okuno; Douglas Hawkins; Joseph Neglia; R Lor Randall; Richard Womer; Leo Mascarenhas; Carola A S Arndt Journal: J Bone Joint Surg Am Date: 2009-03-01 Impact factor: 5.284